ProFound Therapeutics Secures Up to $35M for Preeclampsia Drug Discovery
- Category
- · Funding · Global
- Date
- August 27, 2026
- Source
- Femtech Insider
Summary
ProFound Therapeutics secured an investment commitment of up to $35 million from the Gates Foundation to expand its human proteome research into women’s health. An initial $20 million investment will support the company’s ProFoundry platform and agentic AI capabilities to identify novel biomarkers and first-in-class protein drugs for preeclampsia and eclampsia, which affect an estimated 10 million women globally each year and… The post ProFound Therapeutics Secures Up to $35M for Preeclampsia Drug Discovery first appeared on .
The company works in Maternal & Newborn and Diagnostics, and this round ($35M) is new money into that part of the market. Compare it with other recent rounds to see whether prices here are rising or holding steady.
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- Femtech Insider Primary source
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.